Rationale, design, and experiences from the vanguard phase of the bariatric surgery for the reduction of cardiovascular events (BRAVE) trial
Authors:
- 26 July 2026
- journal article
- Published by Elsevier in American Heart Journal
- Vol. 302, 107544
Abstract
No abstract availableKeywords
Funding Information
- Population Health Research Institute
- Physicians' Services Incorporated Foundation
- Canadian Institutes of Health Research
This publication has 31 references indexed in Scilit:
- Bariatric Metabolic Surgery vs Glucagon-Like Peptide-1 Receptor Agonists and MortalityJAMA Network Open, 2024
- Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristicsAmerican Heart Journal, 2023
- Roux‐en‐Y gastric bypass, sleeve gastrectomy, or one‐anastomosis gastric bypass? A systematic review and meta‐analysis of randomized‐controlled trialsObesity, 2022
- Association of Metabolic Surgery With Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes and ObesityJAMA, 2019
- Remission of Human Type 2 Diabetes Requires Decrease in Liver and Pancreas Fat Content but Is Dependent upon Capacity for β Cell RecoveryCell Metabolism, 2018
- Metabolic SurgeryJACC, 2018
- Bariatric Surgery and Long-term Cardiovascular EventsJAMA, 2012
- Obesity and Cardiovascular DiseaseJACC, 2009
- Obesity and Age of First Non–ST-Segment Elevation Myocardial InfarctionJACC, 2008
- Bariatric SurgeryJAMA, 2004